연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1141. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Oh DY, Lee KW, Lee KH, Sohn CH, Park YS, Zang DY, Ryoo HM, Song HS, Kim JS, Kang HJ, Kim BS, Bang YJ.
Invest New Drugs. 2011 Mar 15. [Epub ahead of print]
Link
1140. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.
Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Cancer Sci. 2011 Jul;102(7):1388-95. doi: 10.1111/j.1349-7006.2011.01944.x. Epub 2011 May 3.
Link
1139. Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer.
Baek SK, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.
BMC Gastroenterol. 2011 May 19;11:56.
Link
1138. Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection.
Lee YG, Han SW, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Ha SW, Bang YJ.
BMC Cancer. 2011 May 21;11:188.
Link
1137. Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal Tract, and Lung).
Kim SJ, Kim JW, Oh DY, Han SW, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.
Am J Clin Oncol. 2011 Jun 8. [Epub ahead of print]
Link
1136. Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer.
Park J, Park E, Han SW, Im SA, Kim TY, Kim WH, Oh DY, Bang YJ.
Invest New Drugs. 2011 Jul 1. [Epub ahead of print]
Link
1135. Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer.
Nam HJ, Ching KA, Kan J, Kim HP, Han SW, Im SA, Kim TY, Christensen JG, Oh DY, Bang YJ.
Mol Cancer Ther. 2012 Feb;11(2):439-51. Epub 2011 Dec 1.
Link
1134. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Park E, Park J, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Int J Oncol. 2012 Apr;40(4):1259-66. doi: 10.3892/ijo.2011.1290. Epub 2011 Dec 8.
Link
1133. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.
Nam HJ, Kim HP, Yoon YK, Song SH, Min AR, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Invest New Drugs. 2011 Dec 25. [Epub ahead of print]
Link
1132. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Kim K, Chie EK, Wu HG, Kim SG, Lee SH, Kang GH, Hyun CL, Ha SW.
Int J Colorectal Dis. 2011 Aug;26(8):1019-23. Epub 2011 Mar 19.
Link